PDSB: PDS Biotechnology Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for PDSB
Across the 20 sessions after earlier PDSB headlines, the stock closed higher 12 times and lower 7 times, with a median move of 7.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | PDSB | SPY |
|---|---|---|---|
| Sep 8, 2026 | PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks | +36.4% | -0.5% |
| Aug 13, 2026 | PDS Biotech Reports Second Quarter 2026 Financial Results | -3.6% | +0.7% |
| Aug 11, 2026 | PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101 | -64.9% | -0.3% |
| May 13, 2026 | PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update | +20.9% | +0.6% |
| May 6, 2026 | PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results | +0.0% | +1.4% |
| Apr 15, 2026 | PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial | +28.3% | +0.8% |
Quantisnow market dataNASDAQ
PDSB
PDS Biotechnology Corporation
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2015
Get push alerts for PDSB
Full PDSB profile on Quantisnow Follow PDSB and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time